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Fanconi anemia is a rare disease characterized by congenital malfor-mations, aplastic anemia, and predisposition to cancer. Despite theconsolidated role of the Fanconi anemia proteins in DNA repair,
their involvement in mitochondrial function is emerging. The purpose of
this work was to assess whether the mitochondrial phenotype, inde-
pendent of genomic integrity, could correlate with patient phenotype.
We evaluated mitochondrial and clinical features of 11 affected individ-
uals homozygous or compound heterozygous for p.His913Pro and
p.Arg951Gln/Trp, the two residues of FANCA that are more frequently
affected in our cohort of patients. Although p.His913Pro and
p.Arg951Gln proteins are stably expressed in cytoplasm, they are unable
to migrate in the nucleus, preventing cells from repairing DNA. In these
cells, the electron transfer between respiring complex I-III is reduced and
the ATP/AMP ratio is impaired with defective ATP production and AMP
accumulation. These activities are intermediate between those observed
in wild-type and FANCA-/- cells, suggesting that the variants at residues
His913 and Arg951 are hypomorphic mutations. Consistent with these
findings, the clinical phenotype of most of the patients carrying these
mutations is mild.  These data further support the recent finding that the
Fanconi anemia proteins play a role in mitochondria, and open up pos-
sibilities for genotype/phenotype studies based on novel mitochondrial
criteria.
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ABSTRACT
Introduction
Fanconi anemia (FA) is a rare autosomal or X-linked recessive disease character-
ized by congenital abnormalities, bone marrow failure, and predisposition to cancer
(mainly leukemia and squamous cell carcinomas). FA is caused by mutations in at
least 22 genes. The FA proteins co-operate in a pathway whose role in maintaining
the genome integrity is well known. In the presence of DNA damage, eight of the
FA proteins, including FANCA, assemble in a nuclear 'core complex' responsible for
monoubiquitination of FANCD2, an FA player that localizes in foci where it inter-
acts with other FA components for DNA repair.1 FA cells are  consistently hypersen-
sitive to interstrand cross-link inducing agents, such as diepoxybutane (DEB) or mit-
omycin C (MMC).
In addition to their nuclear localization, the FA proteins are also localized in the
cytoplasm, where they are likely to be involved in different processes that have yet
to be defined, such as maintenance of mitochondrial aerobic metabolism, suppres-
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Table 1. Molecular and clinical data of Fanconi anemia  individuals with biallelic or monoallelic p.His913Proand p.Arg951Gln alleles of FANCA.
Patient/ Status Mutation Present age Congenital Malformation Hematologic Haematologic
sex (age at diagnosis) malformations score features score
F1/M Homozygous c.2738A>C 11 Bilateral thumb 11 Mild bi-lineage 3
p.His913Pro (10) hypoplasia,  patency Moderate cytopenia; Mild
of the ductusarteriosus no transfusion support
F2/F* Homozygous c.2738A>C 24 Growth delay, strabismus, 2 Cytopenia 7
p.His913Pro (6) astigmatism, microphthalmia, Mild tri-lineage before HSCT Moderate
hypopigmentation (area), (17-year-old); no transfusion 
triangular face, micrognazia before HSCT
F3/M Homozygous   c.2738A>C 26 Growth delay, 10 Leukopenia before 5
p.His913Pro (16) strabismus, myopia, microphthalmia, Moderate HSCT (18-year-old);  HSCT Moderate
widespread hyperpigmentation, no transfusion before
triangular face, visual impairment, 
hypospadias
F4/F Compound c.2738A>C 13 Growth delay, 9 Leukopenia and 6
heterozygous p.His913Pro (4) duodenal atresia, Moderate thrombocytopenia Moderate
c.3715_3729del hyperpigmentation (area), before HSCT (9-year-old); 
p.Glu1239_Arg1243del cafè au lait spots no transfusion before HSCT
F5/M Compound c.2738A>C 18 Growth delay, 22 Cytopenia 11
heterozygous p.His913Pro (7) syndactyly, Severe tri-lineage before HSCT Severe
c.894-?_1470+?del triangular face, unilateral (right) (9-year-old);
renal hypoplasia, micropenis, hypospadias transfusion before HSCT
F6/M Compound c.2738A>C 19 Growth delay, 6 Leukopenia at diagnosis; 2
heterozygous p.His913Pro (15) astigmatism, microphthalmia, Moderate at present, blood count Mild
c.2852G>A widespread hyperpigmentation, in the normal range
p.Arg951Glns triangular face, micrognazia
F7/M Compound c.2852G>A 22 Growth delay, 2 Mild neutropenia 2
heterozygous p.Arg951Gln (11) cutaneous hyperpigmentation Mild Mild
c.284-?_426+?del
p.Gly95Glufs*38
F8/M Compound c.2852G>A Dead at 9 Triangular 1 Thrombocytopenia 9
heterozygous p.Arg951Gln (6) face Mild evolved in severe Severe
c.4261-19_4261-12del tri-lineage cytopenia 
concomitantly with MDS/AML.
Dead after two HSTC for relapse 
(9-year-old)
F9/M Compound c.2852G>A Dead at 21 Growth delay 1 Bi-lineage cytopenia. 7
heterozygous p.Arg951Gln (10) Mild Dead for CMV infection after Moderate
c.3558dup HSCT (21-year-old)
p.Arg1187Glufs*28
F10/M Compound c.2852C>T 15 Growth delay, hyperpigmentation, 7 Thrombocytopenia 8
heterozygous p.Arg951Gln (6) triangular face, unilateral Moderate evolved in tri-lineage Moderate
c.2T>A ectopic kidney cytopenia before HSCT (12-year-old); 
p.? transfusions before HSCT
F11/F* Compound c.2851C>T 20 Microphthalmia, triangular face, 7 At diagnosis mild thrombocytopenia 7
heterozygous p.Arg951Trp (7) hyperpigmentation, Moderate evolved in tri-lineage Moderate
c.1777-7_1779del hearing loss left mild conductive
cytopenia before HSCT (17-year-old); 
transfusions before HSCT
*Potential hematologic mosaicism. In F2 lymphoblasts a de novo compensatory mutation c.2737C>G/p.His913Ala is likely to restore the allele function. In F11 lymphoblast cell
lines the c.1777-7_1779del was not detected, suggesting that a back mutation event occurred in these cells. For all of these patients, it was not possible to establish when and to
what extent the revertant event occurred. 
sion of intracellular reactive oxygen species (ROS) levels,
and protection from proinflammatory cytokine-induced
apoptosis.2 Indeed, FA cells have structurally abnormal
mitochondria, as they appear swollen with matrix rarefac-
tion, altered cristae and reticulum fragmentation.3,4 All
these features further affect the mitochondrial functions,
suppressing cell respiration, perpetuating ROS production
and switching respiration from oxidative phosphorylation
(OXPHOS) to aerobic glycolysis.2-5 
An important milestone in unraveling the role of the FA
proteins in the cytoplasm is the discovery of their involve-
ment in selective autophagy.6 They are fundamental for
removal of damaged mitochondria probably modulating
mitochondrial fission-fusion balance, explaining why
mutations of the FA genes result in accumulation of mor-
phological defective mitochondria and inbalance of the
cellular redox status.6,7
The clinical expressivity in FA is extremely variable
from severe to mild, sometimes without clinical signs.
Except for mutations of the FANCD2 and BRCA2 genes,
no strong association has been found between the clinical
phenotype with the genotype, mainly because of the wide
genetic heterogeneity and the limited number of patients
who belong to rare complementation groups.8,9 Even con-
sidering FANCA, the most frequently mutated gene
accounting for approximately two-thirds of the cases,10 the
spectrum of mutation is extremly heterogeneous with pri-
vate mutations and large intragenic deletions.11,12 
We report functional studies of three missense FANCA
mutations (p.His913Pro,  p.Arg951Gln, and p.Arg951Gln),
whose pathogenic effect in DNA repair is distinct from
that in mitochondrial activity. The mutant proteins are
stably expressed but localized only in the cytoplasm, sug-
gesting that they are functionally inactive at least for the
DNA repair. They are instead functionally hypomorphic
for the mitochondrial function. Consistent with the
hypothesis of a residual activity of p.His913Pro,
p.Arg951Gln, and p.Arg951Trp, the clinical phenotype of
patients carrying these mutations is characterized by late
onset of mild cytopenia, which tends to remain stable dur-
ing follow up.
Methods
Biological samples
Eleven FA probands with positive chromosomal breakage test
were included in this study. The institutional review board of the
“G. Gaslini” Hospital, Genoa, Italy, approved the study, and all the
subjects or their legal guardians gave written informed consent to
the investigation according to the Declaration of Helsinki. In 10
cases (F2-F11), mutations had been previously reported.13 Patient
P1 was a novel case analyzed by next generation sequencing.14
Complementation assay
Lymphoblast (LFB) cells were transduced with retroviral vectors
expressing the cDNAs for FANCA, as previously reported.15,16
Mitomycin C (MMC) survival assay and cell cycle evaluation were
performed as previously described.15 
Western blot and immunofluorescence assay
A full-length FANCA sequence was amplified and cloned into
the pcDNA3.1-Flag tagged expression vector. The mutant FANCA
cDNAs (p.His913Pro and p.Arg951Gln/Trp) were generated by
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Figure 1. Functional studies of the p.His913Pro and p.Arg951Gln variants. (A) Complementation analysis determined as cell survival after mitomycin C (MMC) treat-
ment of lymphoblast (LFB) cells from patients F3 (homozygous for p.His913Pro) and F7 (compound heterozygous for p.Arg951Gln and p.Gly95Glufs*38) transduced
with retroviral vector expressing the wild-type FANCA cDNA. (B and C) Complementation of the G2 cell cycle arrest after melphalan exposure of F3 and F7 LFB. (D
and E) Comparison of the cell survival and cell cycle analysis in LFB cells of patients carrying the p.His913Pro (F3, F4, F5 and F6) and the p.Arg951Gln (F7) mutations
and in control cells: wild-type (+/+) LFB cells and LFB cells not expressing the protein (-/-) due to a homozygous large intragenic deletion (c.284-?_1826+?del) of
FANCA. There is no significant difference between LFB-/- cells and LFB carrying the missense mutations.
A B C
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site-directed mutagenesis using specific primers (available upon
request) and transfected, using calcium phosphate, in 293T cells
treated with 2 mM hydroxyurea (HU) for 24 hours.17 Protein
whole and fractionated cell extracts were prepared using M-PER™
Mammalian Protein Extraction Reagent and NE-PER™ Nuclear
and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific),
respectively. Primary antibodies were used as follows: anti-
FANCA (Savino et al.,18 1:500), anti-FANCD2 (Santa Cruz, sc-
20022, 1:500), add anti-HSP90 (Santa Cruz, sc-7947, 1:4000), anti-
ORC2 (Abcam, ab68348; 1:500), anti-FLAG (OctA Probe H5,
Santa Cruz, 1:500), and anti-α Tubulin (Santa Cruz, sc-5286,
1:2000). Immuno-reactivity was visualized using the Enhanced
Chemiluminescent SuperSignalTm West Femto Maximum
Sensitivity Substrate (Pierce).
For immunofluorescence assay, anti-FLAG antibody was used
with anti-mouse FITC secondary antibody (F0479,
DakoCytomation), while nuclei were stained with 1 ug/mL pro-
pidium iodide solution (Sigma Aldrich). 
Biochemical assays
FANCA pcDNA3.1 constructs were transfected in LFB cells not
expressing the FANCA protein (FANCA-/-) using Lipofectamine
(Thermo Fisher Scientific). Biochemical assays (ATP/AMP evalua-
tion, electron transfer between complex I to complex III and
Oxygen consumption measurements) were performed as
described in Columbaro et al.19
Fo-F1 ATP synthase activity assay
Evaluation of the Fo-F1 ATP synthase activity was performed as
previously described.20 Briefly, 200,000 cells were incubated for 10
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Figure 2. Expression of p.His913Pro and p.Arg951Gln FANCA proteins. (A) Western blot of total lysates from lymphoblast (LFB) cells of patients carrying the
p.His913Pro (F3, F4, F5 and F6) and the p.Arg951Gln (F7 and F10) mutations, showing that the mutant FANCA proteins are expressed. The controls are wild-type
(+/+) LFB cells and LFB cells not expressing the FANCA protein (-/-) due to a homozygous large intragenic deletion (c.284-?_1826+?del) of FANCA. (B) Western blot
of cytoplasmic (C) and nuclear (N) fractionated cellular lysates after 2 mM hydroxyurea treatment (24 hours) of LFB from patients F3 and F7, showing that the
endogenous p.His913Pro and p.Arg951Gln proteins do not translocate to the nucleus. Controls +/+ and -/-, as indicated in (A). (C) Western blot of cytoplasmic (C),
nuclear (N) fractionated, or total (TL) cellular lysates from 293T cells transfected with the wild-type (wt) or the mutant (H913P and R951Q) forms of FANCA tagged
with FLAG, confirming the exogenous p.His913Pro and p.Arg951Gln FANCA proteins are retained in the cytoplasm. (D) Immunofluorescence analyses on 293T cells
transfected as indicated in (C). Nuclei are stained with propidium iodide (PI). (E) Western blot of different LFB cells exposed to 2 mM hydroxyurea (24 hours) showing
no monoubiquitination of the FANCD2 protein. Control +/+, as indicated in (A).
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B
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minutes (min) in a proper medium and ATP synthesis was
induced by the addition of 0.1 mM ADP.  The reaction was mon-
itored for 2 min, every 30 seconds (sec) in a luminometer
(GloMax® 20/20n Luminometer, Promega Italia, Milan, Italy), by
the luciferin/luciferase chemiluminescent method, with ATP stan-
dard solutions between 10-8 and 10-5 M (luciferin/luciferase ATP
bioluminescence assay kit CLSII, Roche, Basel, Switzerland). Data
were expressed as nmol ATP produced/min/106 cells.
The oxidative phosphorylation efficiency (P/O ratio) was calcu-
lated as the ratio between the concentration of the produced ATP
and the amount of consumed oxygen in the presence of respiring
substrate and ADP.21
Clinical data
Clinical information, phenotypic score and grade of cytope-
nia was defined as described in Svahn et al.8 The hematologic
condition was evaluated by scores grouped in three categories,
from 1 to 3, from > 3 to 7, and > 7, representing mild, moderate,
and severe phenotypes, respectively. Regarding the malforma-
tion features, a score was assigned to every patient, dividing the
population into three groups: mild (<6), moderate (6-15), and
severe (>15).
Results
Missense p.His913Pro and p.Arg951Gln mutants 
of FANCA are stably expressed with loss-of-function
effect on DNA repair
In our cohort of FA individuals, there are relatively recur-
rent missense mutations of the FANCA gene, such as
c.2738A>C (p.His913Pro) accounting for 9 alleles from six
different families (Table 1). Three patients were homozy-
gous (F1, F2, and F3) and another 3 (F4, F5 and F6) were
compound heterozygous for the mutation with the second
allele being a small in-frame p.Glu1239_Arg1243del or large
intragenic deletion, and another missense p.Arg951Gln
mutation, respectively. All the six families were from Sicily,
suggesting a founder effect of the c.2738A>C variant.
Indeed, genotyping four polymorphic loci closed to
FANCA, we found that the variant was associated with the
same haplotype in all the families (data not shown).
Bioinformatics tools showed low pathogenicity scores for
p.His913Pro.13 Consistently, the CADD score (score 13.25)
is lower than the threshold (score 15.00) commonly used to
predict pathogenicity of missense variants.22
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Figure 3. Hypomorphic effect of missense mutations on mitochondrial activity. (A) Intracellular concentrations of ATP and AMP, ATP/AMP ratio, and electron transfer
between complex I and III were determined in lymphoblasts (LFB) from patients with mild (F6, F7), moderate (F3, F4) and severe (F6) hematologic scores. LFB from
3 Fanconi anemia (FA) patients not expressing FANCA (-/-) and 5 healthy individuals (+/+) have been used as controls. The three -/- cell lines are compound heterozy-
gous (p.Arg18Profs*19/p.Asn1221Thrfs*26 and p.Ser175Leufs*5/p.Trp183*) and homozygous (Gly95Glufs*31) for nonsense or frameshift mutations. Each graph
is representative of three experiments carried out in each cell line and data are expressed as mean±Standard Deviation (SD). t-test indicates a significant difference
of P<0.05 (*) and P<0.01 (**) between the +/+ cells and the other samples, while # and  ## indicate a significant difference of P<0.05 and P<0.01, respectively,
between the -/- LFB cells and the other samples. (B) The same parameters reported in (A) were evaluated in an LFB -/- cell line transfected with the wild-type (wt) or
mutant (H913P, R951Q and R951W) forms of FANCA tagged with FLAG, showing that the mitochondrial activity is intermediate between that of LFB +/+ and LFB -/-
cells transfected or untransfected (+/+ or -/- vectors) with the empty vector. Each graph is representative of three experiments carried out in each cell line and data
are expressed as mean±Standard Deviation (SD). t-test indicates a significant difference of P<0.05 (* or #) and P<0.01 (** or ##) between LFB cells -/- transfected
with empty vector or expressing the three missense mutant forms of FANCA and  LFB cells +/+ (* and **) or LFB cells -/- (# and ##).
A B
To exclude the possibility that another FA gene or
another unknown FANCA variant in linkage disequilibri-
um with c.2738A>C could be responsible for the disease,
we further investigated the role of FANCA as a disease-
causing gene. First of all, complementation analysis of
FANCA restored the MMC sensitivity and/or G2 arrest
induced by melphalan in LFB homozygous for
p.His913Pro (F3) (Figure 1A and B). Then, to investigate
the functional impact of p.His913Pro on protein stability
and localization, we performed Western blot analysis
using LFB from 4 affected individuals (F3-F6). In all the
four cell lines, FANCA was not degraded and was
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Figure 4. Oxymetric measures and ATP synthesis. (A) Amperometric traces of the oxygen consumption for LFB FANCA-/- cells transfected with wild-type (+/+),
p.His913Pro, p.Arg951Gln, and p.Arg951Trp mutant forms of FANCA. (B) ATP synthesis rate in the same samples as in (A). The data in (A) and (B) are also depicted
as histograms. Each bar graph is representative of three experiments and data are expressed as mean±Standard Deviation (SD). Anova test indicates a significant
difference of P<0.05 (*) and P<0.01 (**) between the +/+ sample and the other samples, while ## indicates a significant difference of P<0.01 between LFB -/-
transfected with the p.His913Pro, p.Arg951Gln and p.Arg951Trp mutant forms of FANCA and LFB -/-.
A
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expressed at similar level as in wild-type cells
(FANCA+/+) (Figure 2A). The protein was instead unde-
tectable, even at different exposures, in LFB (FANCA-/-)
from an FA patient homozygous for a FANCA large intra-
genic deletion (exons 4 to 20) resulting in a frameshift
mutation (p.Gly95Glyfs*31). Finally, in order to evaluate
whether the mutant p.His913Pro protein could play a role
in nuclear DNA repair, we analyzed fractionated cellular
lysates. As expected, FANCA was detected in both cyto-
plasm and nucleus of the wild-type LFB cells. Instead, the
protein was present only in the cytoplasm of cells from F3
(Figure 2B). Immunofluorescence and Western blot of frac-
tionated cellular lysate from the 293T cells over-express-
ing the wild-type or the mutated FANCA tagged with
FLAG confirmed that the mutant protein was retained in
the cytoplasm (Figure 2C and D). Taken together, these
data indicated that the p.His913Pro mutant form of
FANCA is stably expressed but is unable to enter the
nucleus and play its role in the DNA repair pathway. 
Of note, patient F6 is a compound heterozygous for the
p.His913Pro and p.Arg951Gln mutations. The latter was
identified in another 4 probands (F7, F8, F9, and F10) who
are compound heterozygous for deleterious frameshift,
splicing or start-loss mutation of FANCA (Table 1).
Consistent with haplotype analysis (data not shown), the
families carrying p.Arg951Gln come from different geo-
graphical areas, suggesting that the mutation  originated
from independent de novo events and that the presence of
another disease-causing mutation in linkage disequilibri-
um was unlikely. In the LFB cells of F7, the sensitivity to
MMC and the G2 arrest were restored by complementa-
tion analysis (Figure  1A and C). Like the p.His913Pro sub-
stitution, p.Arg951Gln did not affect FANCA stability,
being the protein expressed in LFB of patients F7 and F10
(Figure  2A). Moreover, neither the endogenous nor the
over-expressed mutant protein migrated into the nucleus
(Figure 2B and C).
Taken together, these data suggest that p.His913Pro and
p.Arg951Gln are loss-of-function mutations for the role of
FANCA in controlling the genomic integrity. Consistent
with this hypothesis, FANCD2 was not monoubiquitinat-
ed in any of the six cell lines available for the analysis
(Figure  2E). Moreover, in the same cells, the sensitivity to
MMC and the percentage of cells blocked in the G2 phase
are comparable with those of the FANCA-/- cells (Figure
1D and E).
Finally, at position 951 an additional substitution
(c.2851C>T/p.Arg951Trp) was identified in one allele of
patient F11. However, the LFB cell line or other biological
samples were not available for investigations to confirm
that the mutation is associated with protein stability and
lack of FANCD2 monoubiquitination, as reported by
Karras et al.23
p.His913Pro and p.Arg951Gln are hypomorphic 
mutations for mitochondrial activity
In order to evaluate whether FANCA could affect the
mitochondrial function, we investigated the electron
transport chain functionality and the cellular energy status
in LFB from patients with mild (F6 and F7), moderate (F3
and F4), and severe (F5, the only LFB cell line available
within this group) hematologic score. Consistent with the
FA mitochondrial phenotype,2-4 the cells showed an altered
ATP/AMP ratio with reduced ATP production and AMP
accumulation, and impaired electron transfer between
complexes I and III (Figure 3A). Of note, the biochemical
values were intermediate between those obtained in
FANCA+/+ and FANCA-/- cells, suggesting that
p.His913Pro and p.Arg951Gln are hypomorphic alleles for
the mitochondrial activity.
In order to demonstrate that these alleles are directly
involved in determining a mild mitochondrial phenotype,
we over-expressed the p.His913Pro and p.Arg951Gln, as
well as p.Arg951Trp, FANCA proteins in FANCA-/- cells.
Whereas the ATP and AMP concentrations, the ATP/AMP
ratio, and the electron transport were complemented by
transfection of the wild-type cDNA, the same phenotypes
were only partially restored by expression of the three
mutant cDNAs. Of note, the biochemical measurements
are significantly different when FANCA-/- cells are com-
pared with those over-expressing the mutant forms of
FANCA (Figure 3B).
The defect in the electron transfer between complexes I
and III determines an impaired oxygen consumption and
ATP synthesis in FANCA-/- cells, while in the samples
expressing His913Pro, Arg951Gln and Arg951Trp, this
activity is partially recovered, although with values lower
than those obtained in cells expressing the wild-type
FANCA protein (Figure 4A and B). Conversely, respiration
was observed in all samples after stimulation with succi-
nate, indicating that the electron transfer through complex
II, III and IV pathways is not impaired  (Figure 4A). This
implies that the FA mutations may have a specific interac-
tion with the complexes I, III and IV pathway. However,
similarly to that reported in literature,21 the P/O ratio in
the presence of pyruvate/malate is around 2.5 in all sam-
ples, suggesting that, despite the impaired mitochondrial
function in FANCA-/- and in cells expressing the three
mutant forms of FANCA, the residual oxygen consump-
tion is devoted to ATP synthesis (Figure 4C).
Moderate clinical phenotype in patients with missense
mutations affecting residues His913Pro and Arg951
The clinical data of the affected individuals carrying the
p.His913Pro, p.Arg951Gln, and  p.Arg951Trp mutations
are reported in Table 1. Of the 11 patients, 8 were male
and 3 females. Mean age at diagnosis was 8.9 years (range
4-16 years). Ten had mild or moderate somatic phenotype
(range 1-11). Nine of these individuals had concordant
mild or moderate hematologic scores ranging from 2 to 8.
Three individuals (F1, F6, and F7) had mild cytopenia that
did not require transfusions. Of note, F6 and F7 had a mild
leukopenia/neutropenia at diagnosis; at present, blood
count is in the normal range in F6 and neutropenia is sta-
ble in F7 after 4 and 11 years, respectively, from the first
abnormal blood count. The remaining 6 probands under-
went HSCT. The first abnormal blood count was a mild
tri-lineage cytopenia in F2 and F9 or thrombocytopenia, as
in F10 and F11. They all underwent HSCT for progression
to aplastic anemia, which occurred 10-11 years after diag-
nosis in F2, F9, and F11. Even F3 and F4 did receive HSCT
after two and five years, respectively, of stable moderate
cytopenia because a matched healthy sibling brother was
available. Except for F9, who died for HSCT complica-
tions due to cytomegalovirus infection, the other patients
are all alive after a follow up ranging from 1 to 18 years
(mean 9.5 years) and none have developed hematologic
adverse events (myelodysplastic syndrome, acute myel-
ogenous leukemia or cytogenetic alterations) and/or solid
tumor.
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Patients F5 and F8 were the 2 affected individuals with
severe hematologic scores. In addition to having multiple
congenital malformations (score 22), F5 was characterized
by severe tri-lineage requiring blood transfusions. He suc-
cessfully underwent HSCT two years after diagnosis. At
diagnosis, F8 had no congenital malformation except for
growth delay and mild thrombocytopenia. However, the
mono-lineage cytopenia evolved in severe tri-lineage
cytopenia concomitantly with myelodysplastic syndrome
transformed in acute myelogenous leukemia. He died
three years later for relapse after two HSCT.
Discussion
Mutations of the FA genes are almost private, though
common founder mutations have been reported in few
populations, including Spanish Gypsies, the Afrikaner
population of South Africa, Ashkenazi Jews, and people
from some Italian geographical regions.24-27 This is the case
of p.His913Pro, a mutation of the FANCA gene that is rel-
atively frequent, even as a homozygous condition, in
patients from Sicily. Indeed, the analysis of microsatellite
markers in the six families revealed the presence of a com-
mon haplotype compatible with a founder effect. In con-
trast, p.Arg951Gln has been identified, never as a
homozygous mutation, in individuals from different geo-
graphical areas, suggesting that it occurred as independent
de novo mutational events. At the same residue, an addi-
tional rare pathogenic mutant (p.Arg951Trp) affects one
allele of our cohort of patients.23
Since these alterations are missense mutations, their
pathogenic effect on protein function has been ascertained
by considering several aspects. Unlike p.Arg951Gln/Trp,
p.His913Pro was classified as a variant of uncertain signif-
icance, as the predictive bioinformatic tools indicated that
this amino acid substitution has no or mild effect on pro-
tein function.13 However, genetic studies support their
pathogenic role, as they are present in FA patients and
only rarely in controls (ExAC or other databases).13
Consistent with this hypothesis, we found that the
mutant FANCA proteins (both endogenous and over-
expressed) localize only in the cytoplasm, where they are
stably expressed at similar levels to those observed in
wild-type cells. As a consequence, the FA/BRCA pathway
remains inactive because  FANCD2 is not monoubiquiti-
nated, as demonstrated by Western blot analysis.
These data are consistent with those reported by
Castella et al.,24 who showed that all the FANCA missense
mutations are stably expressed. Like p.His913Pro and
p.Arg951Gln, their products do not enter the nucleus, pre-
venting FANCD2 being monoubiquitinated. On the con-
trary, the same authors demonstrated that null mutations,
such as nonsense or frameshift alterations, are unstable
and not detectable within cells.24 Therefore, our data con-
firm the hypothesis of a correlation between type of
mutation and expression level of mutant FANCA, but as to
why these mutant proteins are retained in the cytoplasm
without any apparent function remains a subject of
debate.
In trying to unravel any role of the FA proteins in other
cell compartments, we investigated the mitochondria
OXPHOS function and the cellular energy status whose
alteration may lead to an impaired mitophagy process.28
As demonstrated by biochemical assays, expression of the
p.His913Pro and p.Arg951Gln/Trp proteins are associated
with a mild mitochondrial function impairment. In partic-
ular, the electron transport between complexes I and III,
the ATP production, and the O2 consumption appear
defective but not to the same extent as in FA cells
homozygous for null mutations. Interestingly, the defec-
tive OXPHOS is limited to the pathway composed by
complexes I, III and IV, considering that the oxygen con-
sumption and the relative ATP synthesis is similar in con-
trol and FA samples when induced by succinate. This sug-
gests that the potential function of FANCA, as well as
other FA proteins, on mitochondria is confined to the
OXPHOS led by complex I. However, the evaluation of
P/O ratio shows that, in all samples, the oxygen consump-
tion, even when very low, is finalized to the ATP synthe-
sis, indicating that the mitochondria are always in a cou-
pled status.
In accordance with the recent discovery that the FA pro-
teins are required for clearance of damaged mitochondria
and to decrease the mitochondrial reactive oxygen
species,6 our finding supports the role of FANCA in these
organelles. Considering that small interfering RNA of the
FA genes is associated with increased puncta, which is a
marker for defects in clearance of damaged mitochondria,6
we can  speculate that mutations of FANCA could nega-
tively influence the efficiency of the mitophagy, causing
an accumulation of damaged mitochondria. This may
determine not only a decrement in the energy production,
but also the increment of oxidative stress, which could
induce  damage of other mitochondria. However, we can-
not exclude the possibility  that the FANCA protein may
have a more direct role in the modulation of the mito-
chondria structure and function, i.e. influencing the organ-
ization of inner mitochondrial membrane, whose integrity
is essential for the proper functioning of the OXPHOS.
Of interest, our data allow us to dissect the activity of
FANCA in DNA repair from that in preserving the mito-
chondrial function, as has previously been hypothesized
for FANCC.6 Indeed, one mutation of this gene (c.67delG),
resulting in an N-terminus truncated but stable mutant
form of FANCC, is unable to repair DNA but is able to
restore the mitochondrial function. Therefore, we regard
the p.His913Pro and p.Arg951Gln/Trp as variants with a
hypomorphic effect of FANCA in maintaining the mito-
chondrial activity.  Even mutations of the FANCD2 gene
have been regarded as hypomorphic.29 However, their
'hypomorphic' effect is associated with the role of the
protein in controlling genomic integrity. In FANCD2 indi-
viduals, at least one allele is always associated with
expression of a low amount of FANCD2, which is
detectable in both the non- and monoubiquitinated form,
suggesting that residual activity of FANCD2 for the DNA
repair processes is essential for life. On the contrary, bial-
lelic null mutations of FANCA and FANCC are relatively
common in FA and are always associated with lack of
FANCD2 monoubiquitination.24
Considering that the c.67delG mutation of FANCC,
which is able to restore the mitochondrial function,6 is
associated with mild clinical phenotypes,9,30 we evaluated
whether we could reach the same conclusion in our
cohort of 11 patients. The mean age (8.9 years) at diagno-
sis was  higher than that reported in the FA Italian cohort
(6.8 years).8 Nine of them had concordant mild/moderate
hematologic and somatic phenotypes. Regarding  malfor-
mations, 4, 6, and one patients were classified as mild,
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moderate and severe, respectively, and percentages [0.36
vs. 0.43 (mild), 0.55 vs. 0.37 (moderate), and 0.09 vs. 0.20
(severe)] are not significantly different from those of the
entire Italian cohort, although only in one case were the
congenital malformations severe. For the hematologic fea-
tures, 3 (0.30), 6 (0.50) and 2 (0.20) of patients received
mild, moderate and severe scores, respectively, compared
with 16% (mild), 27% (moderate), and 49% (severe) of
the FA Italian population, suggesting that the missense
mutations at residues His913 and Arg951 are associated
with better hematologic prognosis.8
Two patients had severe hematologic score and under-
went HSCT (together with another 6 affected individuals).
However, HSCT per se should not be regarded as a marker
of hematologic severity. Indeed, despite their moderate
hematologic condition, 2 patients took advantage of hav-
ing a suitable healthy matched sibling donor, which is
known to provide the best outcome.31 Another 4 under-
went familiar or matched unrelated donor HSCT  even
more than ten years after the first abnormal blood count,
when cytopenia dropped from mild/moderate to severe.
They are alive and well at 3-7 years after HSCT, except for
F9 and F8 who died for cytomegalovirus infection after
HSCT and relapse after two HSCT, respectively. Three
probands (F2, F6, and F7) with mild hematologic score did
not undergo HSCT and their hematologic condition
appears to be stable even 11 years (F7) after diagnosis.
Taken together, these data suggest that FA individuals
carrying the p.His913Pro and p.Arg951Gln/Trp mutations
at one or both the FANCA alleles have a relatively mild
phenotype. This conclusion is consistent with data of
Faivre et al.,9 showing that patients with altered FANCA
protein have milder phenotypes than those with a com-
plete loss of FANCA. However, the clinical phenotype
depends on many factors, including different genetic and
environmental factors, preventing us from confirming any
clear correlations. Although FA affected individuals carry-
ing the same disease-causing mutation (even among sib-
lings) could have different outcomes, the 3 patients
homozygous for p.His913Pro have mild/moderate clinical
phenotype. Of note, our cohort numbers were limited, as
the number of cases studied is relatively low. In order to
assign statistical significance to the correlation, we should
explore whether other FA mutations are hypomorphic for
the mitochondrial activity and eventually correlate this
with mild clinical outcome.
Finally, another factor that could modulate the clinical
phenotype in FA is the occurrence of hematopoietic
mosaicism, in which cells have lost mitomycin C sensitiv-
ity due to back mutations or other genetic mechanisms, as
it occurs in almost 20% of cases.32 In consideration of this,
F2 and F11 are 2 individuals with potential hematopoietic
mosaicism, since one of the two FA mutations was revert-
ed to wild-type allele in their LFB cell lines.13 However,
none of them were further investigated, preventing us
from ascertaining whether and to what extent the
mosaicism was present in the bone marrow and blood
cells.
In conclusion, at least for the mitochondrial activity,
p.His913Pro and p.Arg951Gln/Trp are hypomorphic
mutations, which are associated with a mild/moderate
phenotype characterized by late onset of the disease and
slow hematologic progression. Since the hematopoietic
stem cells are relatively sensitive to their redox status,33 a
residual activity of mitochondria in cells expressing these,
and maybe other missense mutations, could help patients
avoid experiencing worsening cytopenia and postponing
their eligibility for HSCT. Therefore, we should explore
whether other FA mutations with hypomorphic effect
could explain the clinical variability in FA. 
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